Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.36 |
| ▸ | RELA | Q04206 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415863 | 0.71 | CYP17A1 (0.37) | GAACYP17A1ATRPTPN11CA1 | |
| SCHEMBL20689331 | 0.63 | GAA (0.35) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL13055402 | 0.62 | CYP17A1 (0.59) | GAACYP17A1PTPN11CA1 | |
| SCHEMBL21155495 | 0.62 | GAA (0.35) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL29032266 | 0.62 | NFKB1 (0.39) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL14110260 | 0.62 | EPHX2 (0.42) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL977487 | 0.60 | CYP17A1 (0.54) | CYP17A1PTPN11CA1 | |
| SCHEMBL28269645 | 0.59 | NFKB1 (0.42) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL27991298 | 0.59 | NFKB1 (0.42) | NFKB1NFKB2RELAGAACYP17A1 | |
| SCHEMBL2880191 | 0.59 | LMNA (0.54) | BRD4GAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | NFKB1 1236/4885NFKB2 1404/4885RELA 1082/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | NFKB1 1236/4885NFKB2 1404/4885RELA 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.